Eija Roine1, Harri Sintonen2, Pirkko-Liisa Kellokumpu-Lehtinen3, Heidi Penttinen4, Meri Utriainen4, Leena Vehmanen4, Riikka Huovinen5, Hannu Kautiainen6, Riku Nikander7, Carl Blomqvist8, Liisa Hakamies-Blomqvist4, Tiina Saarto4. 1. Helsinki University Hospital, Comprehensive Cancer Center, and University of Helsinki, Faculty of Medicine, Helsinki, Finland. Electronic address: eija.roine@helsinki.fi. 2. University of Helsinki, Department of Public Health, Helsinki, Finland. 3. Tampere University, Faculty of Medicine and Medical Technology, and Tampere University Hospital, Cancer Center, Center of Research, Development and Innovation, Tampere, Finland. 4. Helsinki University Hospital, Comprehensive Cancer Center, and University of Helsinki, Faculty of Medicine, Helsinki, Finland. 5. Turku University Hospital, Department of Oncology, and University of Turku, Faculty of Medicine, Turku, Finland. 6. Kuopio University Hospital, Primary Health Care Unit, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland. 7. University of Jyväskylä, Faculty of Sport and Health Sciences, GeroCenter Foundation for Aging Research & Development, and Central Finland Hospital District, Department of Research & Education, Jyväskylä, Finland. 8. Helsinki University Hospital, Comprehensive Cancer Center, and University of Helsinki, Faculty of Medicine, Helsinki, Finland; Örebro University Hospital, Department of Oncology, Örebro, Sweden.
Abstract
OBJECTIVE: To investigate long-term health-related quality of life (HRQoL) changes over time in younger compared to older disease-free breast cancer survivors who participated in a prospective randomized exercise trial. METHODS:Survivors (aged 35-68 years) were randomized to a 12-month exercise trial after adjuvant treatment and followed up for ten years. HRQoL was assessed with the generic 15D instrument during follow-up and the younger (baseline age ≤ 50) and older (age >50) survivors' HRQoL was compared to that of the age-matched general female population (n = 892). The analysis included 342 survivors. RESULTS: The decline of HRQoL compared to the population was steeper and recovery slower in the younger survivors (p for interaction < 0.001). The impairment was also larger among the younger survivors (p = 0.027) whose mean HRQoL deteriorated for three years after treatment and started to slowly improve thereafter but still remained below the population level after ten years (difference -0.017, 95% CI: -0.031 to -0.004). The older survivors' mean HRQoL gradually approached the population level during the first five years but also remained below it at ten years (difference -0.019, 95% CI: -0.031 to -0.007). The largest differences were on the dimensions of sleeping and sexual activity, on which both age groups remained below the population level throughout the follow-up. CONCLUSIONS:HRQoL developed differently in younger and older survivors both regarding the most affected dimensions of HRQoL and the timing of the changes during follow-up. HRQoL of both age groups remained below the population level even ten years after treatment.
RCT Entities:
OBJECTIVE: To investigate long-term health-related quality of life (HRQoL) changes over time in younger compared to older disease-free breast cancer survivors who participated in a prospective randomized exercise trial. METHODS: Survivors (aged 35-68 years) were randomized to a 12-month exercise trial after adjuvant treatment and followed up for ten years. HRQoL was assessed with the generic 15D instrument during follow-up and the younger (baseline age ≤ 50) and older (age >50) survivors' HRQoL was compared to that of the age-matched general female population (n = 892). The analysis included 342 survivors. RESULTS: The decline of HRQoL compared to the population was steeper and recovery slower in the younger survivors (p for interaction < 0.001). The impairment was also larger among the younger survivors (p = 0.027) whose mean HRQoL deteriorated for three years after treatment and started to slowly improve thereafter but still remained below the population level after ten years (difference -0.017, 95% CI: -0.031 to -0.004). The older survivors' mean HRQoL gradually approached the population level during the first five years but also remained below it at ten years (difference -0.019, 95% CI: -0.031 to -0.007). The largest differences were on the dimensions of sleeping and sexual activity, on which both age groups remained below the population level throughout the follow-up. CONCLUSIONS: HRQoL developed differently in younger and older survivors both regarding the most affected dimensions of HRQoL and the timing of the changes during follow-up. HRQoL of both age groups remained below the population level even ten years after treatment.
Authors: Kristina Engvall; Henrik Gréen; Mats Fredrikson; Magnus Lagerlund; Freddi Lewin; Elisabeth Åvall-Lundqvist Journal: Breast Cancer Res Treat Date: 2022-08-09 Impact factor: 4.624